Introduction
Colorectal cancer (CRC) ranks among the leading causes of cancer-related mortality globally, with the etiology reflecting a complex interplay of genetic and environmental factors. A fraction of CRC patients benefit from immunotherapy, particularly those with mismatch repair deficiency. However, for those with mismatch repair-proficient (MMRp) colorectal tumors, the benefits are less pronounced. A study by Llosa et al. (2019) enriches the understanding of the tumor microenvironment in MMRp CRC and opens new avenues for combinatorial immunotherapy strategies by targeting adaptive immune resistance mechanisms.
The Clinical Cancer Research journal detailed the findings and implications in their September 2019 issue, elaborating on the response of patients with MMRp to anti-PD-1 monotherapy and the role of intratumoral IL17-mediated signaling (DOI: 10.1158/1078-0432.CCR-19-0114).
Key Findings
1. Intratumoral Adaptive Immunosuppression
The study elucidates the adaptive immune suppression often exhibited by tumors. Tumors can modify their microenvironment to evade immune detection and destruction, a process known as adaptive immune resistance. In the context of MMRp colorectal tumors, Llosa et al., observed that the presence of a preexisting antitumor immune response does not necessarily predict a clinical benefit to T-cell checkpoint inhibitors, which are a class of drugs designed to unmask cancer cells and make them vulnerable to immune attack. This underlines the complexity of the immune landscape within tumors and the need for a deeper understanding of its components.
2. IL17 and Type 17 Immunity in MMRp Colorectal Tumors
The study underscored the importance of Type 17 immunity, characterized by the presence of interleukin 17 (IL17). IL17 is known to play a role in inflammation and the defense against some pathogens, but its presence in MMRp colorectal cancer has been correlated with limited responses to immunotherapy. This finding revealed that IL17-mediated signaling pathways could create an immunosuppressive environment conducive to tumor growth and resistance to immunotherapeutic drugs.
Combining IL17 Inhibitors and Immunotherapy
The presence of drugs targeting the IL17 signaling pathway in clinical settings provides a compelling case for combinatory treatment approaches. Drugs such as secukinumab have shown promising results in the treatment of autoimmune diseases by inhibiting IL17 and could potentially augment the efficacy of immune checkpoint blockers in treating CRC.
Keywords
1. MMRp Colorectal Cancer Immunotherapy
2. IL17 Inhibition in CRC
3. Adaptive Immunosuppression in Cancer
4. T-cell Checkpoint Inhibitors
5. Intratumoral Immune Response
Discussion and Analysis
Interpreting Tumor Immune Evasion Tactics:
The research shines a spotlight on the immunological maneuvers that cancer cells employ. Cancer seeks to dodge immune surveillance by creating a microenvironment that suppresses effective immune responses. In particular, MMRp CRC has a more convoluted immune environment compared to their mismatch repair-deficient counterparts.
Role of IL17 in Counteracting Immune Activity:
Elevated IL17 levels in the tumor milieu emerging from this research signify a new adversary in the battle against CRC. IL17 might be operating as a shield for cancer cells, subduing the otherwise preexisting antitumor immune cells. Hence, disrupting the IL17 stronghold presents an inviting target for enhancing the anticancer efficacy of existing immunotherapies.
Implications for Personalized Medicine:
The study propels the field of personalized medicine forward by suggesting that biomarkers such as IL17 could be critical in stratifying patients who would most likely benefit from specific immunotherapy combinations. This information is vital for oncologists and researchers as they navigate the complex treatment landscape of CRC.
Potential for Combinatorial Therapeutic Strategies:
The apparent adaptability and resilience of MMRp CRC illuminate the potential in combinatorial therapeutic strategies. Drugs modulating the IL17 axis, combined with immune checkpoint blockade therapies, might prove to be a paradigm shift in how CRC is treated, especially in the subset of patients with traditionally less responsive tumor profiles.
Future Research Directions:
While the study by Llosa et al. (2019) provides critical insights, it also paves the way for further research. Key areas would include the development of combination trials, longitudinal studies to observe the evolution of the immune landscape post-treatment, and the mechanistic dissection of IL17’s role in tumorigenesis and immune suppression.
Conclusion
The study spearheaded by Llosa and colleagues breaks new ground in the scientific understanding of the immune evasion strategies employed by MMRp colorectal cancers. It highlights the crucial role of IL17 in blunting the effectiveness of T-cell checkpoint inhibitors, thus pointing to the potential of developing novel combinatorial approaches that leverage IL17 inhibition to potentiate immunotherapeutic outcomes. This research accentuates the urgent need to personalize cancer treatment further and innovate more effective modalities for those suffering from this challenging disease.
References
1. Llosa NJ, et al. (2019). Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clinical Cancer Research, 25(17), 5250-5259. DOI: 10.1158/1078-0432.CCR-19-0114
2. Topalian SL, Drake CG, Pardoll DM. (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell, 27, 450–461. DOI: 10.1016/j.ccell.2015.03.001
3. Le DT, et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357, 409–413. DOI: 10.1126/science.aan6733
4. Bendell J, et al. (2018). LBA-004 Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann Oncol, 29(suppl_5). DOI:10.1093/annonc/mdy424.004
5. Smith KN, et al. (2019). Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. J Immunother Cancer, 7, 40. DOI: 10.1186/s40425-019-0524-2